July 06, 2011

Sanofi and Rib-X Pharmaceuticals Sign a Research Collaboration Agreement on Novel Classes of Antibiotics

 

Sanofi and Rib-X Pharmaceuticals Sign a Research Collaboration Agreement on Novel Classes of Antibiotics

Paris, France – July 6, 2011 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the signature of an exclusive worldwide research collaboration agreement and option for license with Rib-X Pharmaceuticals, Inc. for novel classes of antibiotics resulting from Rib-X’s RX-04 program for the treatment of resistant Gram-positive and resistant Gram-negative pathogens.